biologics
Leveraging the EHR Among Tools for Boosting Biosimilars
Despite the promise of huge savings with biosimilars—an estimated $140 billion in discounted spending over ...
OCTOBER 28, 2021
Nearly 1 in 3 IBD Patients Stops Biologic Therapy Within 18 Months
Almost one-third of people followed in an inflammatory bowel disease registry stopped biologic therapy within 1.5 ...
OCTOBER 26, 2021
In New Guidance, Society Recommends Certain Vaccines, Drug Timing for Rheumatology Patients
The American College of Rheumatology has released new updates to its COVID-19 clinical guidance that call for ...
AUGUST 24, 2021
Anifrolumab Infusion Reduces SLE Joint Disease, Tenderness and Rash
A post hoc analysis of pooled phase 3 clinical trial data has found anifrolumab-fnia reduced joint disease and ...
JULY 15, 2021
IBD Patients Report Their Reactions To Biological Therapies
When IBD patients self-report their adverse reactions to biological therapies, they could provide insights that ...
APRIL 26, 2021
Overcoming Biosimilar Hesitancy
Biosimilars have the potential to significantly reduce costs for medical centers, but the adoption rate is still ...
JANUARY 8, 2021
Multidisciplinary Specialty Care Team Approach Improves Biosimilar Adoption
A multidisciplinary specialty care team approach was significantly more successful in converting patients to ...
NOVEMBER 30, 2020
Studies: Most SLE, Arthritis Patients Not at Higher Risk for COVID Hospitalization
Patients with systemic lupus erythematosus or inflammatory arthritis conditions such as rheumatoid arthritis may ...
SEPTEMBER 25, 2020
FDA Approves New Treatment for Nonradiographic Axial Spondyloarthritis
The FDA approved a supplemental Biologics License Application for ixekizumab injection for the treatment of active ...
JUNE 2, 2020
FDA Approves Adakveo for Painful Complication of Sickle Cell Disease
The FDA approved crizanlizumab-tmca for sickle cell patients 16 and older who suffer vaso-occlusive crisis, a ...
NOVEMBER 19, 2019
FDA Approves First Treatment for Reducing Attack Frequency of Cluster Headache
The FDA approved galcanezumab-gnlm (Emgality, Lilly) solution for injection for the treatment of episodic cluster ...
JULY 15, 2019
When to Stop, Start Meds for Rheumatic Patients Undergoing Hip and Knee Replacements
Periprosthetic joint infections are associated with high morbidity and mortality; perioperative management ...
JUNE 30, 2017
